The Nigerian e-health company Famasi has secured a pre-seed round of investment. Originally founded as a drug management service, Famasi has since broadened its mission to include the construction of pharmacy infrastructure to scale digital health.
Famasi Famasi is a digital health platform that was introduced in 2021 by Adeola Ayoola and Umar Faruq Akinwunmi. It enables people to access their medications, receive doorstep delivery, automate monthly refills, take advantage of free follow-up visits, and communicate with healthcare professionals.
“When we started, we realised there was a huge infrastructure gap and we had to build ours from scratch. Access to medications is a problem that’s bigger than one startup,” Ayoola said. “However, we believe that with the proper infrastructure, we can offer more personalisation with our B2C offering while enabling more digital health solutions to not just be born, but thrive.”
With participation from Ore Ogundipe, GetEquity SPV, Isaac Ewaleifoh, Ibrahim Bello, Ayobami Olufadeji, Yusuf Abdulmalik, Adeline Okoh, Echezona Uzoma, Lanre Adelowo, Prosper Otemuyiwa, and Nadayar Enegesi, Microtraction is leading the pre-seed round for Famasi.
“With this funding, we’re lucky to partner with investors who believe in this mission, including some of our early customers who connect deeply with the problem,” Ayoola said.
By the end of 2023, the business plans to add more than 35,000 consumers from its pipeline and increase the number of its suppliers from 229 to 1,000, according to Faruq.
“We’re on a mission to power one million refills by 2027. We’re very lucky to have an amazing team where everyone is connected to the problem and passionate about solving it for themselves and their loves. We’re on track to simplify & personalise medication management at scale, starting with our APIs,” he said.